- Conditions
- Metastatic Invasive Lobular Carcinoma (mILC)
- Interventions
- circulating tumor DNA (ctDNA)
- Diagnostic Test
- Lead sponsor
- Julia Foldi
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 919
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 566
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 342 more
- Conditions
- Bladder Cancer
- Interventions
- Atezolizumab, Bacille Calmette-Guérin
- Drug · Biological
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more
- Conditions
- Breast Cancer, Ductal Carcinoma in Situ - Category
- Interventions
- (18F)FES, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Bladder Cancer
- Interventions
- CG0070
- Biological
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 13 more
- Conditions
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Interventions
- PD-L1/IDO Peptide Vaccine, Pembrolizumab
- Biological
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Lung Cancer (Diagnosis)
- Interventions
- Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Fallopian Tube Patency Tests, Fibroid/Myoma (Uterus/Cervix), Myomectomy, Fallopian Tube Disease
- Interventions
- chromopertubation
- Procedure
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- ENDOMETRIAL CANCER
- Interventions
- Surgery with UM, Surgery without UM
- Device
- Lead sponsor
- Anthony Costales, MD
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Cleveland, Ohio • Houston, Texas
- Conditions
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec
- Drug
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 79
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 70 more
- Conditions
- Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Tubular Ductal Breast Carcinoma
- Interventions
- External beam radiation therapy
- Radiation
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • Salt Lake City, Utah
- Conditions
- Breast Cancer
- Interventions
- Molecular Breast Imaging (MBI), Tc99m sestamibi
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Triple-negative Breast Cancer
- Interventions
- Tempus assay, Advanced pathology 1, Advanced pathology 2
- Other
- Lead sponsor
- Laura Kennedy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer
- Interventions
- mammography
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 311
- States / cities
- Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more
- Conditions
- Lung Cancer (Diagnosis)
- Interventions
- Standard medical treatment
- Other
- Lead sponsor
- bioAffinity Technologies Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 2,063 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Grand Junction, Colorado • Bay Pines, Florida + 8 more
- Conditions
- Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
- Interventions
- LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
- Drug
- Lead sponsor
- Integro Theranostics
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
- Conditions
- Metastatic Invasive Breast Cancer, Metastatic Invasive Gynecologic Cancer
- Interventions
- Acceptance- and mindfulness-based physical activity promotion
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
- Interventions
- Infigratinib, Placebo
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 47
- States / cities
- Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Invasive Bladder Cancer
- Interventions
- HIPEC
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bladder Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Stage IV Breast Cancer
- Interventions
- positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy, Immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Bladder Cancer
- Interventions
- filgrastim, cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York